Biohaven Ltd
BHVN
Market Cap$3.52B
Close$
$3.07
92.3% downside
Current Fair Value
92.3% downsideOvervalued by 92.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.52 Billion |
|---|---|
| Enterprise Value | $3.98 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.0 |
| Beta | 1.71 |
| Outstanding Shares | 88,258,441 |
| Avg 30 Day Volume | 1,449,639 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.0 |
|---|---|
| PEG | 0.0 |
| Price to Sales | 4.43 |
| Price to Book Ratio | -3.99 |
| Enterprise Value to Revenue | 4.62 |
| Enterprise Value to EBIT | -6.16 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.25 |
| Debt to Equity | -1.26 |
Revenue Sources
No data
ESG Score
No data
About Biohaven Pharmaceutical Holding Company Ltd
CEO: Vlad Coric